Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Sarcoma 85Lymphoma 58Lymphoma, Large B-Cell, Diffuse 55Lymphoma, Non-Hodgkin 34Osteosarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Hodgkin Disease 25Burkitt Lymphoma 24Testicular Neoplasms 22Neuroectodermal Tumors, Primitive, Peripheral 19Ovarian Neoplasms 18Leukemia 18Lymphoma, Follicular 17Fibrosarcoma 16Testicular Germ Cell Tumor 15Neuroblastoma 15Teratoma 14Rhabdomyosarcoma 14Lymphoma, Large-Cell, Immunoblastic 14Liposarcoma 14Lymphoma, Mantle-Cell 13Lymphoma, Large-Cell, Anaplastic 13Hemangiosarcoma 13Recurrence 12Neurofibrosarcoma 12Leiomyosarcoma 12Histiocytoma, Malignant Fibrous 12Central Nervous System Neoplasms 12Sarcoma, Synovial 11Lymphoma, B-Cell, Marginal Zone 11

Interventions

Rituximab 7Cyclophosphamide 7dacetuzumab 6fludarabine 5fludarabine phosphate 4blinatumomab 4Bortezomib 4ibrutinib 3Melphalan 3Lenalidomide 3Ifosfamide 3Etoposide 3Dexamethasone 3Bendamustine Hydrochloride 3ponatinib 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Doxorubicin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2AP 1903 reagent 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Immunoproliferative Disorders × Ifosfamide × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Seagen Inc.

Phase 2 Terminated
151 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡